RevenueNet IncomeP/EP/SEBITDividendStocksMarket capitalizationDebtLiabilitiesEquityAAQSEmployeesROEROAROCE
Pluristem Therapeutics Stock

Pluristem Therapeutics EBIT 2025

Pluristem Therapeutics EBIT

-4.7 M USD

Ticker

PSTI

ISIN

US72940R3003

WKN

A2PPB4

In 2025, Pluristem Therapeutics's EBIT was -4.7 M USD, a 38.62% increase from the -3.39 M USD EBIT recorded in the previous year.

The Pluristem Therapeutics EBIT history

YEAREBIT (undefined USD)
2026e-6.64
2025e-4.7
2024e-3.39
2023e-46.53
2022e-42.33
202150.62
2020-29.48
2019-35.53
2018-33.73
2017-28.02
2016-23.32
2015-25.27
2014-27.85
2013-22.22
2012-15.03
2011-11.11
2010-7.44
2009-6.56
2008-10.43
2007-6.28
2006-2.33
2005-2.66
2004-3.01
2003-0.21
2002-0.07

Pluristem Therapeutics Revenue, EBIT, Net Income

  • 3 years

  • 5 years

  • 10 years

  • 25 Years

  • Max

Revenue
EBIT
Net Income
Details

Revenue, EBIT and Profit

ⓘ

Understanding Revenue, EBIT, and Income

Gain insights into Pluristem Therapeutics, a comprehensive overview of its financial performance can be obtained by analyzing the Revenue, EBIT, and Income chart. Revenue represents the total income generated by Pluristem Therapeutics from its primary operations, showcasing the company’s ability to attract and retain clients. EBIT, or Earnings Before Interest and Taxes, indicates the company’s operational profitability, free from the influence of tax and interest expenses. The Income section reflects Pluristem Therapeutics’s net earnings, an ultimate measure of its financial health and profitability.

Yearly Analysis and Comparisons

Observe the yearly bars to understand the annual performance and growth of Pluristem Therapeutics. Compare the Revenue, EBIT, and Income to evaluate the company’s efficiency and profitability. A higher EBIT compared to the previous year suggests an improvement in operational efficiency. Likewise, an increase in Income indicates enhanced overall profitability. Analyzing the year-to-year comparison assists investors in understanding the company’s growth trajectory and operational efficiency.

Utilizing Expectations for Investment

The expected values for the forthcoming years offer investors a glimpse into Pluristem Therapeutics’s anticipated financial performance. Analyzing these projections alongside historical data aids in making informed investment decisions. Investors can gauge the potential risks and returns, aligning their investment strategies accordingly to optimize profitability and mitigate risks.

Investment Insights

Leveraging the comparison between Revenue and EBIT helps in assessing Pluristem Therapeutics’s operational efficiency, while the Revenue and Income comparison reveals the net profitability after accounting for all expenses. Investors can derive valuable insights by meticulously analyzing these financial parameters, laying the foundation for strategic investment decisions aimed at capitalizing on Pluristem Therapeutics’s growth potential.

Pluristem Therapeutics Revenue, EBIT and net profit per share

DatePluristem Therapeutics RevenuePluristem Therapeutics EBITPluristem Therapeutics Net Income
2026e174.46 M undefined-6.64 M undefined-2.24 M undefined
2025e99.45 M undefined-4.7 M undefined-1.9 M undefined
2024e57.83 M undefined-3.39 M undefined-1.65 M undefined
2023e32.96 M undefined-46.53 M undefined-54.44 M undefined
2022e0 undefined-42.33 M undefined-33.65 M undefined
20210 undefined50.62 M undefined49.87 M undefined
202020,000 undefined-29.48 M undefined-29.15 M undefined
201950,000 undefined-35.53 M undefined-35.31 M undefined
201850,000 undefined-33.73 M undefined-26.13 M undefined
20170 undefined-28.02 M undefined-27.81 M undefined
20162.85 M undefined-23.32 M undefined-23.25 M undefined
2015380,000 undefined-25.27 M undefined-24.68 M undefined
2014380,000 undefined-27.85 M undefined-26.93 M undefined
2013680,000 undefined-22.22 M undefined-21.16 M undefined
2012720,000 undefined-15.03 M undefined-14.79 M undefined
20110 undefined-11.11 M undefined-10.85 M undefined
20100 undefined-7.44 M undefined-7.45 M undefined
20090 undefined-6.56 M undefined-6.64 M undefined
20080 undefined-10.43 M undefined-10.5 M undefined
20070 undefined-6.28 M undefined-8.43 M undefined
20060 undefined-2.33 M undefined-2.44 M undefined
20050 undefined-2.66 M undefined-2.1 M undefined
20040 undefined-3.01 M undefined-2.01 M undefined
20030 undefined-210,000 undefined-460,000 undefined
20020 undefined-70,000 undefined-80,000 undefined

Pluristem Therapeutics stock margins

The Pluristem Therapeutics margin analysis displays the gross margin, EBIT margin, as well as the profit margin of Pluristem Therapeutics. The EBIT margin (EBIT/sales) indicates the percentage of sales that remains as operating profit. The profit margin shows the percentage of sales that remains for Pluristem Therapeutics.

  • 3 years

  • 5 years

  • 10 years

  • 25 Years

  • Max

Gross margin
EBIT margin
Profit margin
Details

Margin

ⓘ

Understanding Gross Margin

The gross margin, expressed as a percentage, delineates the gross profit made from the Pluristem Therapeutics's sales revenue. A higher gross margin percentage indicates that the Pluristem Therapeutics retains more revenue after accounting for the costs of goods sold. Investors use this metric to gauge financial health and operational efficiency, as well as to compare it with competitors and industry averages.

EBIT Margin Analysis

EBIT margin represents the Pluristem Therapeutics's earnings before interest and taxes. Analyzing the EBIT margin over different years provides insights into the operational profitability and efficiency, excluding the effects of financial leverage and tax structure. A growing EBIT margin over the years signifies improving operational performance.

Revenue Margin Insights

The revenue margin demonstrates the Pluristem Therapeutics's total revenue generated. When comparing the revenue margin year over year, investors can gauge the Pluristem Therapeutics's growth and market expansion. It is essential to compare the revenue margin with the gross and EBIT margins to understand the cost and profit structures better.

Interpreting Expectations

The expected values for gross, EBIT, and revenue margins provide future financial outlook of the Pluristem Therapeutics. Investors should compare these expectations with historical data to understand potential growth and risk factors. It is crucial to consider the underlying assumptions and methodologies used in projecting these expected values to make informed investment decisions.

Comparative Analysis

Comparing the gross, EBIT, and revenue margins, both yearly and over multiple years, enables investors to perform a comprehensive analysis of the Pluristem Therapeutics's financial health and growth prospects. Evaluating the trends and patterns in these margins helps in identifying strengths, weaknesses, and potential investment opportunities.

Pluristem Therapeutics Margin History

Pluristem Therapeutics Gross marginPluristem Therapeutics Profit marginPluristem Therapeutics EBIT marginPluristem Therapeutics Profit margin
2026e100 %-3.81 %-1.28 %
2025e100 %-4.72 %-1.91 %
2024e100 %-5.86 %-2.85 %
2023e100 %-141.17 %-165.16 %
2022e100 %0 %0 %
2021100 %0 %0 %
2020100 %-147,400 %-145,750 %
2019100 %-71,060 %-70,620 %
2018100 %-67,460 %-52,260 %
2017100 %0 %0 %
201696.49 %-818.25 %-815.79 %
201597.37 %-6,650 %-6,494.74 %
201497.37 %-7,328.95 %-7,086.84 %
201397.06 %-3,267.65 %-3,111.76 %
201297.22 %-2,087.5 %-2,054.17 %
2011100 %0 %0 %
2010100 %0 %0 %
2009100 %0 %0 %
2008100 %0 %0 %
2007100 %0 %0 %
2006100 %0 %0 %
2005100 %0 %0 %
2004100 %0 %0 %
2003100 %0 %0 %
2002100 %0 %0 %

Pluristem Therapeutics Aktienanalyse

What does Pluristem Therapeutics do?

Pluristem Therapeutics Inc is a biopharmaceutical company specializing in the discovery and development of cell therapies, as well as the manufacturing of autologous cell therapies. The company was founded in 2001 and is headquartered in Haifa, Israel. They have employees in Israel and the USA. Pluristem Therapeutics Inc's business model is focused on the research, development, and manufacturing of cell therapies, with a focus on autologous cell therapies. They have multiple divisions focused on developing cell therapies for various diseases. The company also offers products based on the use of stem cells, such as placenta-expanded cells (PLX), which can be used for muscle regeneration and treating inflammation. Pluristem Therapeutics Inc has achieved significant success in the development of cell therapies, including obtaining approval for a clinical trial in Europe for the use of PLX-PAD in critical limb ischemia (CLI). They are a leading company in the field of cell therapies, with a unique platform technology for the expansion and utilization of human stem cells. Pluristem Therapeutics ist eines der beliebtesten Unternehmen auf Eulerpool.com.

EBIT Details

Analyzing Pluristem Therapeutics's EBIT

Pluristem Therapeutics's Earnings Before Interest and Taxes (EBIT) represents the company's operating profit. It is calculated by deducting all operating expenses, including the cost of goods sold (COGS) and operating expenses, from the total revenue, but before accounting for interest and taxes. It provides insights into the company’s operational profitability, excluding the impacts of financing and tax structures.

Year-to-Year Comparison

A yearly comparison of Pluristem Therapeutics's EBIT can reveal trends in the company’s operational efficiency and profitability. An increase in EBIT over the years can indicate enhanced operational efficiency or growth in revenue, while a decrease might raise concerns about increased operating costs or declining sales.

Impact on Investments

Pluristem Therapeutics's EBIT is a significant metric for investors. A positive EBIT suggests that the company is generating enough revenue to cover its operating expenses, an essential aspect for assessing the company’s financial health and stability. Investors closely monitor EBIT to gauge the company’s profitability and potential for future growth.

Interpreting EBIT Fluctuations

Fluctuations in Pluristem Therapeutics’s EBIT can be due to variations in revenue, operating expenses, or both. An increasing EBIT indicates improved operational performance or increased sales, while a declining EBIT can signal rising operational costs or reduced revenue, prompting a need for strategic adjustments.

Frequently Asked Questions about Pluristem Therapeutics stock

How much did Pluristem Therapeutics achieve in EBIT for the current year?

In the current year, Pluristem Therapeutics has achieved an EBIT of -4.7 M USD.

What is EBIT?

EBIT stands for Earnings Before Interest and Taxes and refers to the profit before interest and taxes of a company Pluristem Therapeutics.

How has the EBIT of Pluristem Therapeutics developed in recent years?

The EBIT of Pluristem Therapeutics has increased by 38.622% increased compared to the previous year.

What does EBIT mean for investors?

EBIT provides investors with insights into a company's profitability as it reflects the profit before interest expenses and taxes.

Why is EBIT an important indicator for investors?

Since EBIT provides a more direct insight into a company's profit than net income, it is an important indicator for investors to assess the profitability of a company.

Why do EBIT values fluctuate?

EBIT values can fluctuate as they are influenced by various factors, such as revenue, costs, and tax effects.

What role does tax burden play in EBIT?

Tax burdens have a direct impact on a company's EBIT, as they are deducted from the profit.

How is EBIT presented in the balance sheet of the company Pluristem Therapeutics?

The EBIT of Pluristem Therapeutics is listed in the income statement.

Can EBIT be used as a single indicator for evaluating a company?

EBIT is an important indicator for evaluating a company, but additional financial ratios should also be considered to get a comprehensive picture.

Why is EBIT not equal to net profit?

The net profit of a company includes taxes and interest, while EBIT represents the profit before interest and taxes.

How much dividend does Pluristem Therapeutics pay?

Over the past 12 months, Pluristem Therapeutics paid a dividend of . This corresponds to a dividend yield of about . For the coming 12 months, Pluristem Therapeutics is expected to pay a dividend of 0 USD.

What is the dividend yield of Pluristem Therapeutics?

The current dividend yield of Pluristem Therapeutics is .

When does Pluristem Therapeutics pay dividends?

Pluristem Therapeutics pays a quarterly dividend. This is distributed in the months of .

How secure is the dividend of Pluristem Therapeutics?

Pluristem Therapeutics paid dividends every year for the past 0 years.

What is the dividend of Pluristem Therapeutics?

For the upcoming 12 months, dividends amounting to 0 USD are expected. This corresponds to a dividend yield of 0 %.

In which sector is Pluristem Therapeutics located?

Pluristem Therapeutics is assigned to the 'Health' sector.

Wann musste ich die Aktien von Pluristem Therapeutics kaufen, um die vorherige Dividende zu erhalten?

To receive the latest dividend of Pluristem Therapeutics from 7/4/2025 amounting to 0 USD, you needed to have the stock in your portfolio before the ex-date on 7/4/2025.

When did Pluristem Therapeutics pay the last dividend?

The last dividend was paid out on 7/4/2025.

What was the dividend of Pluristem Therapeutics in the year 2024?

In the year 2024, Pluristem Therapeutics distributed 0 USD as dividends.

In which currency does Pluristem Therapeutics pay out the dividend?

The dividends of Pluristem Therapeutics are distributed in USD.

Stock savings plans offer an attractive way for investors to build wealth over the long term. One of the main advantages is the so-called cost-average effect: by regularly investing a fixed amount in stocks or stock funds, you automatically buy more shares when prices are low, and fewer when they are high. This can lead to a more favorable average price per share over time. In addition, stock savings plans allow small investors access to expensive stocks, as they can participate with small amounts. Regular investment also promotes a disciplined investment strategy and helps to avoid emotional decisions, such as impulsive buying or selling. Furthermore, investors benefit from the potential appreciation of the stocks as well as from dividend distributions, which can be reinvested, enhancing the compounding effect and thus the growth of the invested capital.

Andere Kennzahlen von Pluristem Therapeutics

Our stock analysis for Pluristem Therapeutics Revenue stock includes important financial indicators such as revenue, profit, P/E ratio, P/S ratio, EBIT, as well as information on dividends. We also assess aspects such as stocks, market capitalization, debt, equity, and liabilities of Pluristem Therapeutics Revenue. If you are looking for more detailed information on these topics, we offer comprehensive analyses on our subpages.